WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global
biopharmaceutical company committed to becoming a leader in the development and
commercialization of immunology-based therapies, today announced the appointment
of Orlando Oliveira as its Chief Commercial Officer. With a career spanning
nearly 25 years, Mr. Oliveira brings a wealth of experience building high-
performing global commercial teams, driving revenue growth, and fostering
strategic partnerships in the biotechnology and pharmaceutical industry.
"As we continue to advance multiple mid- to late-stage clinical development
programs, we are thrilled to welcome Orlando to the Zenas leadership team," said
Joe Farmer, President and Chief Operating Officer. "His expertise and track
record of building and leading high performing commercial teams will be
instrumental in the establishment of the obexelimab franchise and achievement of
our goal to bring obexelimab to patients worldwide. We will benefit immensely
from Orlando's broad commercial knowledge and leadership as Zenas evolves to
become an integrated development and commercial biopharmaceutical company."
"I am eager to join the seasoned executive team Zenas has built, guided by their
mission to deliver transformative immunology-based therapies to patients in
need," said Mr. Oliveira. "I look forward to working with this team to further
develop and execute the strategies and plans for the eventual commercialization
of obexelimab and to establish Zenas as a leading global immunology-based
development and commercial company."
Prior to joining Zenas, Mr. Oliveira served as Senior Vice President & Head of
International at Mirati Therapeutics (acquired by Bristol Meyers Squibb), where
he helped lead and set up the international foundations of the company and
prepared multiple oncology launches, including leading the European Medicines
Agency approval of KRAZATI(®). Previously, he served as Senior Vice President &
General Manager International at Agios Pharmaceuticals (oncology business
acquired by Servier), and in the same capacity at TESARO (acquired by
GlaxoSmithKline). Previously, he served as Vice President Europe &
Intercontinental Operations at Cubist Pharmaceuticals (acquired by Merck). Mr.
Oliveira also held, during more than a decade, numerous roles of increasing
responsibility at Amgen. Mr. Oliveira currently serves as a Board member at
OncoInvent AS, a privately held clinical-stage radiopharmaceutical company. He
obtained a degree in Pharmacy and a post-graduate degree in Drug and Pharmacy
Law from the University of Coimbra, Portugal.
About Zenas BioPharma
Zenas BioPharma is a clinical-stage global biopharmaceutical company committed
to becoming a leader in the development and commercialization of immunology-
based therapies for patients in need. With clinical development capabilities and
operations globally, Zenas is advancing a portfolio of potentially
differentiated autoimmune therapeutics in areas of high unmet medical need.
Zenas' experienced leadership team and network of business partners drive
operational excellence to deliver potentially transformative therapies to
improve the lives of those facing autoimmune diseases. For more information
about Zenas BioPharma, please visit www.zenasbio.com
(http://www.zenasbio.com/) and follow us on X at @ZenasBioPharma
(https://twitter.com/ZenasBioPharma) and LinkedIn
(https://www.linkedin.com/company/zenas-biopharma/).
Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com (mailto:Zenas@argotpartners.com)
Â